A-385358 NEW
| Price | $55 | $117 | $177 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-06-18 |
Product Details
| Product Name: A-385358 | CAS No.: 406228-55-5 |
| Purity: 97.40% | Supply Ability: 10g |
| Release date: 2025/06/18 |
Product Introduction
Bioactivity
| Name | A-385358 |
| Description | A-385358 is a selective Bcl-xL inhibitor with Kis of 0.80 nM for Bcl-xL and 67 nM for Bcl-2, respectively. |
| In vitro | In IL-3-deprived FL5.12/Bcl-XL cells, A-385358 results in cell killing with an EC50 of 0.47 μM and increases caspase-3 activity. The EC50 of A-385358 for IL-3-depleted FL5.12/Bcl-2 cells with an EC50 of 1.9 μM which is 4-fold higher relative to the cytokine-deprived FL5.12/Bcl-XL cells. A-385358 stimulates more cytochrome c release from mitochondria isolated from FL5.12/Bcl-XL versus Bcl-2 cells[1]. |
| In vivo | The combination of A-385358 (75 mg/kg) plus paclitaxel (30 mg/kg) is well tolerated and inhibits tumor growth rate by nearly 80%. A-385358 exhibits slow but steady increase in the tumor growth. The combination of A-385358 (100 mg/kg) and a lower dose of paclitaxel produces a significant reduction in tumor growth and yields a >100% increase in time for tumors to reach 900 mm3 (%ILS)[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (70.33 mM), Sonication is recommended. |
| Keywords | Inhibitor | inhibit | Bcl-xL | Bcl-2 Family | Bcl-2 | A-385358 | A385358 | A 385358 |
| Inhibitors Related | Gossypol (acetic acid) | (S)-(+)-Ibuprofen | Allethrin | Erianin | Navitoclax | Gossypol | Triacetylresveratrol | Diphenyl disulfide | Lisaftoclax | Venetoclax | Sonrotoclax TFA | Thymoquinone |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Hematonosis Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | PPI Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2.00/100kg |
VIP1Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2025-08-07 | |
| $6.00/1kg |
HebeiShuoshengImportandExportco.,Ltd
|
2024-08-05 | ||
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $55.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-06-18 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY